This study aimed to explore the efficacy and safety of the BTK inhibitor zanubrutinib combined with Pola-R-CHP regimen (or zanubrutinib combined with rituximab and high-dose MTX in primary central nervous system DLBCL, etc.) in patients of DLBCL with specific risk factors (IPI score two points or more, ABC subtypes, double expressor lymphoma, double hit lymphoma, CD5 positive DLBCL, MCD subtypes, N1 subtypes, A53 subtypes, extranodal lesions of 2 or more, special locations involved, such as the central nervous system (CNS, breast, testes).
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Pathologically confirmed diffuse large B-cell lymphoma (DLBCL);
Have a "measurable lesions" ;
Have at least one of the following risk factors, including: IPI score ≥2 points, ABC subtype, double-expressor lymphoma, double-hit lymphoma, CD5-positive DLBCL, MCD subtype, N1 subtype, A53 subtype, extranodal lesions ≥2, special site involvement, such as central nervous system CNS, breast, testis, ovary, uterus, bone marrow, vitreoretinal, paraspinal, paranasal sinuses and intravascular, etc.
ECOG score 0-3;
Expected survival time for 3 months or more;
White blood cell count ≥3 x 10e9/L, the platelet count≥50 x 10e9/L; 1.5 mg/dL or less of serum creatinine, creatinine clearance≥50 ml/min; ALT, AST 3 x ULN or less, total bilirubin 2 x ULN or less.
You may not be if
currently suffering from other malignant tumor;
ever received any treatments for lymphoma, except for short-term use of corticosteroids;
Allergic to any kind of study drug;
Active infection or uncontrol of HBV infection, HIV/AIDS or other serious infectious diseases;
Pregnancy and lactation women of childbearing age and are reluctant to take contraception subjects;
Researchers think that the subject does not fit to participate in this study.